Physician profile
Phillip K Hall
NPI 1144248493
$1,283.18
in general payments reported to CMS, 2019-2025
15 companies · $38.44 in 2025
The $38.44 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $84.48 · 2021: $266 · 2022: $342 · 2023: $184 · 2024: $35.69 · 2025: $38.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $242 · Education: $15.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $241.73 |
| Education | $15.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $328.56 | 2019-2024 | Erivedge |
| Regeneron Healthcare Solutions, INC. | $274.61 | 2019-2024 | Libtayo |
| Novartis Pharmaceuticals Corporation | $124.48 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $114.30 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $103.88 | 2019-2023 | |
| Abbvie INC. | $91.96 | 2019-2021 | |
| Genzyme Corporation | $52.42 | 2021-2023 | |
| Incyte Corporation | $46.72 | 2022-2025 | Opzelura |
| Amgen INC. | $39.61 | 2020-2023 | Otezla |
| Galderma Laboratories, L.P. | $33.73 | 2021 | |
| Pfizer INC. | $18.58 | 2019 | |
| Vyne Pharmaceuticals INC. | $14.91 | 2021 | |
| Leo Pharma INC. | $14.70 | 2021 | |
| Lilly USA, LLC | $12.82 | 2019 | |
| Celgene Corporation | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.